October 27, 2015
SHIELD Evaluates Symic Biomedical's SB-030 to Reduce Short-Term Neointimal Hyperplasia After PTA
October 27, 2015—Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix, announced the treatment of the first patient in the SHIELD trial, a phase 1/2 clinical study in humans to investigate the efficacy and safety of luminal SB-030 delivery in peripheral artery disease (PAD).
According to Symic Biomedical, the study will evaluate SB-030 (previously SBCV-030), a locally applied, single-use treatment for the reduction of neointimal hyperplasia resulting from vascular injury after percutaneous transluminal angioplasty. This multicenter, parallel, blinded, randomized clinical trial is designed to compare the safety and efficacy of balloon angioplasty with or without the addition of SB-030 in PAD patients undergoing procedures for stenosis or occlusion within the superficial femoral artery.
SB‐030 is engineered to mimic the healing and protective effects of naturally occurring proteoglycans. It reduces acute extracellular matrix‐mediated inflammation and thus reduces neointimal hyperplasia, which is the leading cause of restenosis, noted the company.
Andrew Holden, MD, commented in the company’s announcement, “SB‐030 represents a truly novel approach in the field of vascular intervention, particularly for patients being treated for PAD. We are excited to be a lead center in the evaluation of this treatment as part of the SHIELD trial.” Dr. Holden is Director of interventional services at Auckland City Hospital and Associate Professor of Radiology at Auckland University School of Medicine in Auckland, New Zealand.